Global Frontotemporal Disorders Treatment Market, By Drug Class (Antidepressants (Selective serotonin reuptake inhibitors, Serotonin and noradrenaline reuptake inhibitors), Antipsychotics (RIsperidone , Quetiapine), Others), Treatment (Behavioral Symptoms Management, Psychological Symptoms Management), Route of Administration (Oral, Parenteral), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2029.
Frontotemporal Disorders Treatment Market Analysis and Size
Frontotemporal disorders treatment market is expected to witness significant growth during the forecast period. The degeneration of frontotemporal lob is mainly triggered because of proteins involvement TDP43 and tau that directly outbreak the damage on the temporal and frontal lobes of the brain. Although the cause for frontotemporal disorders is still unknown, it largely affects individuals aged 40 to 60 years. COVID-19 also had a major impact on the market growth.
Data Bridge Market Research analyses a growth rate in the global frontotemporal disorders treatment market in the forecast period 2022-2029. The expected CAGR of global frontotemporal disorders treatment market is tend to be around 4.50% in the mentioned forecast period. The market was valued at USD 350 million in 2021, and it would grow upto USD 497.74 million by 2029. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Market Definition
Frontotemporal disorders are also known as frontotemporal lobar degeneration, which is a brain disorder affecting mostly the frontal and temporal lobes of the brain. It is typically characterized by progressive nerve cell loss and dementia. The average age range for the onset of frontotemporal disorder is 40 to 60 years; although it can start after 60 years of age, and the maximum life expectancy is 8–10 years post-diagnosis. It is of great importance to the healthcare sector and thus is expected to rise high in the forecast period.
Frontotemporal Disorders Treatment Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Drug Class (Antidepressants, Antipsychotics, Others), Treatment (Behavioral Symptoms Management, Psychological Symptoms Management), Route of Administration (Oral, Parenteral), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Teva Pharmaceutical Industries Ltd (Israel), Mylan N.V (U.S.), Johnsons & Johnsons Services Inc (U.S.), F. Hoffman-La Roche Ltd. (Switzerland), Lilly (U.S.), Merck & Co., Inc. (U.S.), Aurobindo Pharma (India), Bristol-Myers Squibb Company (U.S.), GSK plc (U.K.), Ascendis Pharma A/S (Denmark), Lupin (India), Hikma Pharmaceuticals PLC (U.K.)
|
|
Market Opportunities
|
|
Global Frontotemporal Disorders Treatment Market Dynamics
Drivers
- Increasing FTD Drug Development and Increasing Funds
Non-profit organizations and disease advocacy & private organizations presently are focusing on supporting FTD drug development as the patient population is expanding. Research funding initiatives by several non-profit organizations such as the Association for Frontotemporal Degeneration (AFTD), Bluefield Project Organization, Tau Consortium Organization, Alzheimer Discovery Foundation (ADDF), and CurePSP, Inc. have facilitated to stimulate research initiatives in frontotemporal disorders treatment drugs. These organizations support clinical as well as preclinical trials for testing novel therapeutics that are interventional to either slow or stop FTD and other rare neurological disease progressions. This boosts the market growth.
- Rising Demand for Oral Drugs
Oral drugs is expected to boost the market growth. The segment is expected to accelerate the global market as most products are available in capsule and tablet form and it is a very feasible route of administration.
Opportunities
- Increase in Elderly Population
Increasing life expectancy rate is another main factor expected to boost the frontotemporal disorders treatment market growth because of the high incidence of neurological disease among the elderly population. People aged 65 years and above are typically susceptible to neurodegenerative diseases such as frontotemporal disorder, Alzheimer’s, and dementia. Thus, this population demands better treatment options and as a result create opportunities for the market growth.
- Higher Drug Approvals and Advanced Treatment
Several antidepressant drugs are used for the treatment of major depressive disorders and other conditions, such as dysthymia, obsessive-compulsive disorder (OCD), anxiety disorders, eating disorders, chronic pain, neuropathic pain. For instance, in October 2018, Lundbeck launched Brintellix tablets that are used for treating Major Depressive Disorder in India. Likewise, in April 2019, Lupin has launched antidepressant Fluoxetine tablets in the American market. The tablets are specified for the treatment of the major depressive disorder, obsessive-compulsive disorder. Thus, these policies drive the market growth.
Restraints/Challenges
- Misdiagnosis of Neurological Disorders
Several frontotemporal disorders are often misdiagnosed as depression, Parkinson’s, Alzheimer’s, or other psychiatric conditions, thus limiting the possibility of adopting neurological conditions treatment.
- Drug Trial Failures
Even though clinical trials have resulted in numerous interventions other than medications, the continuous high rate of clinical trial failures is a major factor that impels the growth prospects of neurological conditions treatment. Thus, it limits the growth of the market.
This global frontotemporal disorders treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global frontotemporal disorders treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on Global Frontotemporal Disorders Treatment Market
The COVID-19 pandemic deeply damaged the frontotemporal disorders treatment market. An upsurge in infection fear among people of all ages has resulted from the growing rate of COVID-positive cases that have resulted in mortality and morbidity worldwide. In addition, the pandemic limits on travel and movement, and hospital beds reserved for COVID patients reduced clinical and hospital visits.
Though, the arrival of virtual healthcare consultations and remote patient monitoring, as well as the rise in COVID-19 vaccines and lifting of lockdown limitations, will allow the market for frontotemporal disorders treatment devices to quickly recover and grow majorly during the coming years. As a result, the market is projected to grow at a fast pace during the forecast period.
Global Frontotemporal Disorders Treatment Market Scope
The global frontotemporal disorders treatment market is segmented on the drug class, treatment, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Drug Class
- Antidepressants
- Selective serotonin reuptake inhibitors
- Serotonin and noradrenaline reuptake inhibitors
- Antipsychotics
- RIsperidone
- Quetiapine
- Others
Treatment
- Behavioral Symptoms Management
- Psychological Symptoms Management
Route of Administration
- Oral
- Parenteral
End-Users
- Hospitals
- Homecare
- Speciality Centres
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Frontotemporal Disorders Treatment Market Regional Analysis/Insights
The global frontotemporal disorders treatment market is analyzed and market size insights and trends are provided by drug class, treatment, route of administration, distribution channel and end-user as referenced above.
The major countries covered in the global frontotemporal disorders treatment market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America is expected to have the highest market growth due to the high-income of the countries and advanced healthcare facilities.
Asia-Pacific dominates the market due to the increase government initiatives and presence of generic companies.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Frontotemporal Disorders Treatment Market Share Analysis
The global frontotemporal disorders treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global frontotemporal disorders treatment market.
Key players operating in the global frontotemporal disorders treatment market include:
- Teva Pharmaceutical Industries Ltd (Israel)
- Mylan N.V (U.S.)
- Johnsons & Johnsons Services Inc (U.S.)
- F. Hoffman-La Roche Ltd. (Switzerland)
- Lilly (U.S.)
- Merck & Co., Inc. (U.S.)
- Aurobindo Pharma (India)
- Bristol-Myers Squibb Company (U.S.)
- GSK plc (U.K.)
- Ascendis Pharma A/S (Denmark)
- Lupin (India)
- Hikma Pharmaceuticals PLC (U.K.)
SKU-